01513 LIVZON PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 2.15X | Oper Margin | 24.5% |
|---|---|---|---|
| LT Debt/Equity | 10.7% | Net Margin | 17.5% |
| Total Debt/Equity | 28.4% | Return on Equity | 14.9% |
| Price/Book | 2.45X | Return on Assets | 8.4% |
| (HKD 39.700) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 2,191.98 | 2,153.31 | 2,140.83 | 2,171.84 | 2,035.26 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +1.8 | +0.6 | -1.4 | +6.7 | +39.7 |
| Earnings Per Share (HKD) | 2.382 | 2.318 | 2.29 | 2.322 | 2.174 |
| Earnings Per Share Growth (%) | +2.8 | +1.2 | -1.4 | +6.8 | +39.5 |
| Dividend Per Share (HKD) | 1.199 | 1.482 | 1.744 | 1.512 | 1.506 |
| P/E* (X) | 16.67 | 17.13 | 17.34 | 17.10 | 18.26 |
| Yield (%) | 3.02 | 3.73 | 4.39 | 3.81 | 3.79 |
| Dividend Share (%) | 50.33 | 63.95 | 76.16 | 65.10 | 69.26 |
| Book NAV (HKD) | 16.177 | 16.752 | 16.630 | 16.959 | 15.208 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-22 21:40:20
Latest Result
| (RMBMn) | 2025-03 | 2024-03 | Chg* (%) | 2023-03 |
| Cover Period (mths) | 3 | 3 | NA | 3 |
|---|---|---|---|---|
| Turnover | 3,181 | 3,243 | -1.9 | 3,413 |
| Operating Result | 944.871 | 834.666 | +13.2 | 724.832 |
| Associates | 14.14 | 13.914 | +1.6 | 13.462 |
| Profit Before Taxation | 958.59 | 844.441 | +13.5 | 735.441 |
| Taxation | 154.948 | 128.362 | +20.7 | 121.579 |
| Profit /( Loss) After Taxation | 803.642 | 716.079 | +12.2 | 613.862 |
| Minority Interests | 166.934 | 108.255 | +54.2 | 31.953 |
| Net Profit | 636.708 | 607.824 | +4.8 | 581.909 |
| Earnings Per Share () | 0.7617 | 0.7041 | +8.2 | 0.7087 |
| Announcement Date | 2025-04-23 | 2024-04-23 | NA | 2023-04-20 |
* Annualised
Last Update Time: 2025-07-22 21:40:25
